专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007031720A1 1,2-DIARYLIMIDAZOLES FOR USE AS CBI MODULATORS 审中-公开
标题翻译：用作CBI调节剂的1,2-二胺基咪唑
公开(公告)号：WO2007031720A1
公开(公告)日：2007-03-22
申请号：PCT/GB2006/003356
申请日：2006-09-12
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , AHLQVIST, Matti , CHENG, Leifeng , LUNDQVIST, Robert , SÖRENSEN, Henrik
发明人： AHLQVIST, Matti , CHENG, Leifeng , LUNDQVIST, Robert , SÖRENSEN, Henrik
IPC分类号： C07D233/90 , C07D401/12 , C07D409/12 , A61K31/4178 , A61P25/00
CPC分类号： C07D233/90 , C07D401/12 , C07D409/12
摘要： Salts of 1,2-diarylimidazole-4-carboxamides and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 1,2-二芳基咪唑-4-甲酰胺的盐和制备这些化合物的方法，它们在治疗肥胖症，精神病学和神经障碍中的用途，其治疗用途的方法和含有它们的药物组合物。

2. 发明申请

WO2007020388A1 PYRAZOLE DERIVATIVES AS THERAPEUTIC AGENTS 审中-公开
标题翻译：作为治疗剂的吡唑衍生物
公开(公告)号：WO2007020388A1
公开(公告)日：2007-02-22
申请号：PCT/GB2006/002990
申请日：2006-08-09
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , AHLQVIST, Matti , CHENG, Leifeng , LUNDQVIST, Robert , SÖRENSEN, Henrik
发明人： AHLQVIST, Matti , CHENG, Leifeng , LUNDQVIST, Robert , SÖRENSEN, Henrik
IPC分类号： C07D401/12 , C07D401/14 , A61K31/415 , A61P3/04
CPC分类号： C07D401/14 , C07D401/12
摘要： Salts of 1,5-diarylpyrazole-3-carboxamides and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译： 1,5-二芳基吡唑-3-甲酰胺的盐和制备这些化合物的方法，它们在治疗肥胖，精神和神经障碍中的应用，其治疗用途的方法和含有它们的药物组合物。

3. 发明申请

WO2006067443A1 THERAPEUTIC AGENTS 审中-公开
标题翻译：治疗药剂
公开(公告)号：WO2006067443A1
公开(公告)日：2006-06-29
申请号：PCT/GB2005/004977
申请日：2005-12-21
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , CHENG, Leifeng
发明人： CHENG, Leifeng
IPC分类号： C07D231/22 , C07D231/24 , A61K31/415 , A61P25/00
CPC分类号： C07D231/14 , C07D401/12
摘要： The present invention relates to 1,5-diphenylpyrazole compounds of formula I (A chemical formula should be inserted here - please see paper copy enclosed herewith) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译：本发明涉及式I的1,5-二苯基吡唑化合物（这里应插入一种化学式，请参见随附的纸质复制品）及其制备方法，用于治疗肥胖症，精神病和神经障碍，其治疗用途的方法和含有它们的药物组合物。

4. 发明申请

WO2004111033A1 2-SUBSTITUED 5, 6-DIARYL-PYRAZINE DERIVATIVES AS CB1 MODULATOR. 审中-公开
标题翻译： 2-取代的5,6-二氨基吡啶衍生物作为CB1调节剂。
公开(公告)号：WO2004111033A1
公开(公告)日：2004-12-23
申请号：PCT/SE2004/000969
申请日：2004-06-16
申请人： ASTRAZENECA AB , CHENG, Leifeng , BERGGREN, Kristina , ELEBRING, Thomas , SÖRENSEN, Henrik
发明人： CHENG, Leifeng , BERGGREN, Kristina , ELEBRING, Thomas , SÖRENSEN, Henrik
IPC分类号： C07D401/12
CPC分类号： C07D241/24 , C07D241/12 , C07D401/12 , C07D403/06
摘要： The present invention relates to 5, 6-diaryl-pyrazine-2-carboxamide and- 2-ester derivatives and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them. The compounds are cannabinoid receptor 1 (CB1) modulators.
摘要翻译：本发明涉及5,6-二芳基 - 吡嗪-2-甲酰胺和-2-酯衍生物及其制备方法，它们在治疗肥胖症，精神病学和神经障碍学中的应用，用于治疗用途的方法和含有它们的药物组合物。这些化合物是大麻素受体1（CB1）调节剂。

5. 发明申请

WO2008120000A1 THERAPEUTIC AGENTS 审中-公开
标题翻译：治疗药剂
公开(公告)号：WO2008120000A1
公开(公告)日：2008-10-09
申请号：PCT/GB2008/001165
申请日：2008-04-02
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , CHENG, Leifeng , HELGESSON, Sara, Annelie , JUDKINS, Robert, Andrew , LINDHAGEN, Marika, Jenny, Susanna , PONTÉN, John, Fritiof
发明人： CHENG, Leifeng , HELGESSON, Sara, Annelie , JUDKINS, Robert, Andrew , LINDHAGEN, Marika, Jenny, Susanna , PONTÉN, John, Fritiof
IPC分类号： C07D471/04 , A61K31/437 , A61P3/04
CPC分类号： C07D471/04
摘要： Certain 4, 5, 6, 7 -tetrahydropyrrolo[3,2-c]pyridin-4-one and 4, 5 -dihydropyrrolo[3,2- c ]pyridin-4-one compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, methods for their therapeutic use and pharmaceutical compositions containing them are described.
摘要翻译：一些式（I）的4,5,6,7-四氢吡咯并[3,2-c]吡啶-4-酮和4,5,5-二氢吡咯并[3,2-c]吡啶-4-酮化合物，制备描述了这些化合物，它们在治疗肥胖症，精神病学和神经病学障碍中的用途，其治疗用途的方法和含有它们的药物组合物。

6. 发明申请

WO2007031721A1 MIDAZOLE-4-CARBOXAMIDE DERIVATIVES FOR USE AS CB MODULATORS 审中-公开
标题翻译：用作CB调节剂的中间体4-羧酰胺衍生物
公开(公告)号：WO2007031721A1
公开(公告)日：2007-03-22
申请号：PCT/GB2006/003358
申请日：2006-09-12
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , CHENG, Leifeng
发明人： CHENG, Leifeng
IPC分类号： C07D401/12 , C07D233/90 , A61K31/55 , A61K31/417 , A61P3/04
CPC分类号： C07D233/90 , C07D401/12
摘要： The present invention relates to substituted 1,2-diphenylimidazol-4-carboxamide compounds of formula (I) to processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译：本发明涉及式（I）的取代的1,2-二苯基咪唑-4-甲酰胺化合物，其用于制备这些化合物，它们在治疗肥胖，精神和神经障碍中的用途，用于治疗用途的方法和药物含有它们的组合物。

7. 发明申请

WO2007010222A2 THERAPEUTIC AGENTS 审中-公开
标题翻译：治疗剂
公开(公告)号：WO2007010222A2
公开(公告)日：2007-01-25
申请号：PCT/GB2006/002638
申请日：2006-07-17
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , BOSTROM, Jonas , CHENG, Leifeng , OLSSON, Roine
发明人： BOSTROM, Jonas , CHENG, Leifeng , OLSSON, Roine
IPC分类号： C07D231/14 , C07D233/90 , C07D207/34 , C07D277/56
CPC分类号： C07D213/83 , C07D207/34 , C07D231/14 , C07D233/90 , C07D239/28 , C07D277/56
摘要： The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译：本发明涉及式（I）化合物及其制备方法，其在治疗肥胖症，精神病和神经疾病中的用途，治疗用途的方法和含有它们。

8. 发明申请

WO2005095354A1 THERAPEUTIC AGENTS 审中-公开
标题翻译：治疗药剂
公开(公告)号：WO2005095354A1
公开(公告)日：2005-10-13
申请号：PCT/GB2005/001153
申请日：2005-03-30
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , CHENG, Leifeng , LINDSTEDT-ALSTERMARK, Eva-Lotte , BOIJE, Anna, Maria, Persdotter
发明人： CHENG, Leifeng , LINDSTEDT-ALSTERMARK, Eva-Lotte , BOIJE, Anna, Maria, Persdotter
IPC分类号： C07D233/54
CPC分类号： C07D233/64 , C07D233/66 , C07D401/12 , C07D409/12
摘要： The present invention relates to compounds of formula (I) and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译：本发明涉及式（I）化合物及其制备方法，它们在治疗肥胖症，精神病学和神经障碍学中的用途及其治疗用途的方法以及含有它们的药物组合物。

9. 发明申请

WO2004058249A1 1,5-DIARYL-PYRROLE-3-CARBOXAMIDE DERIVATIVES AND THEIR USE AS CANNABINOID RECEPTOR MODULATORS 审中-公开
标题翻译： 1,5-二氨基-3-吡啶酰胺衍生物及其作为CANNABINOID受体调节剂的用途
公开(公告)号：WO2004058249A1
公开(公告)日：2004-07-15
申请号：PCT/GB2003/005569
申请日：2003-12-18
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , BERGGREN, Anna, Ingrid, Kristina , BOSTROM, Stig, Jonas , CHENG, Leifeng , ELEBRING, Stig, Thomas , GREASLEY, Peter , NAGARD, Mats , WILSTERMANN, Johan, Michael , TERRICABRAS, Emma
发明人： BERGGREN, Anna, Ingrid, Kristina , BOSTROM, Stig, Jonas , CHENG, Leifeng , ELEBRING, Stig, Thomas , GREASLEY, Peter , NAGARD, Mats , WILSTERMANN, Johan, Michael , TERRICABRAS, Emma
IPC分类号： A61K31/402
CPC分类号： C07D401/04 , A61K31/402 , A61K31/4025 , A61K31/454 , C07D207/34 , C07D401/06
摘要： The present invention relates to a compound of formula (I) (A chemical formula should be inserted here - please see paper copy enclosed herewith) in which R 1 and R 2 independently represent phenyl, thienyl or pyridyl each of which is optionally substituted by one, two or three groups represented by Z; and R 3 is H, a C 1-3 alkyl group, a C 1-3 alkoxymethyl group, trifluoromethyl, a hydroxyC 1-3 alkyl group, an aminoC 1-3 alkyl group, C 1-3 alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C 1-3 alkylcarbamoyl, acetyl, or hydrazinocarbonyl of formula -CONHNR a R b wherein R a and R b are as defined for R 4 and R 5 respectively; X is CO or SO 2 ; Y is absent or represents NH optionally substituted by a C 1-3 alkyl group; R 4 and R 5 independently represent: a C 1-6 alkyl group; an (amino)C 1-4 alkyl- group in which the amino is optionally substituted by one or more C 1-3 alkyl groups; an optionally substituted non-aromatic C 3-15 carbocyclic group; a (C 3-12 cycloalkyl)C 1-3 alkyl- group; a group -(CH 2 ) r (phenyl ) s ; naphthyl; anthracenyl; a saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen wherein the heterocyclic group is optionally substituted ;1-adamantylmethyl; a group - (CH 2 ) t Het where Het represents an aromatic heterocycle optionally substituted; or R 4 represents H and R 5 is as defined above; or R 4 and R 5 together with the nitrogen atom to which they are attached represent a saturated 5 to 8 membered heterocyclic group; R 6 is H, a C 1-3 alkyl group, a C 1-3 alkoxymethyl group, trifluoromethyl, a hydroxyC 1-3 alkyl group, C 1-3 alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C 1-3 alkylcarbamoyl, acetyl, or hydrazinocarbonyl of formula -CONHNR a R b ; with provisos; to processes for preparing such compounds, to their use in the treatment of obesity, psychiatric and neurological disorders particularly obesity, to methods for their therapeutic use and to pharmaceutical compositions containing them.
摘要翻译：本发明涉及式（I）化合物（此处应插入化学式 - 请参见随附的纸质复制品），其中R 1和R 2独立地表示苯基，噻吩基或吡啶基，其各自为任选被一个，两个或三个由Z表示的基团取代; R 3为H，C 1-3烷基，C 1-3烷氧基甲基，三氟甲基，羟基C 1-3烷基，氨基C 1-3烷基，C 1-3烷氧基羰基，羧基，氰基，氨基甲酰基，一或二C 1-3烷基氨基甲酰基，乙酰基或肼基羰基，其中R a和R b分别如R 4和R 5所定义; X是CO或SO2; Y不存在或表示任选被C 1-3烷基取代的NH; R 4和R 5独立地表示：C 1-6烷基; 氨基被一个或多个C 1-3烷基任选取代的（氨基）C 1-4烷基 - 基团; 任选取代的非芳族C 3-15碳环基团; （C3-12环烷基）C1-3烷基; 基团 - （CH 2）r（苯基）s; 萘; 蒽; 含有一个氮的饱和5至8元杂环基和任选的以下之一：氧，硫或另外的氮，其中杂环基任选被取代; 1-金刚烷基甲基; 基团 - （CH 2）t Het，其中Het表示任选取代的芳族杂环; 或R 4表示H且R 5如上所定义; 或R 4和R 5与它们所连接的氮原子一起表示饱和的5至8元杂环基; R 6是H，C 1-3烷基，C 1-3烷氧基甲基，三氟甲基，羟基C 1-3烷基，C 1-3烷氧基羰基，羧基，氰基，氨基甲酰基，一或二C 1-3烷基氨基甲酰基，乙酰基或肼基羰基 -CONHNR

10. 发明申请

WO2008119999A1 THERAPEUTIC AGENTS 审中-公开
标题翻译：治疗药剂
公开(公告)号：WO2008119999A1
公开(公告)日：2008-10-09
申请号：PCT/GB2008/001164
申请日：2008-04-02
申请人： ASTRAZENECA AB , ASTRAZENECA UK LIMITED , CHENG, Leifeng , HELGESSON, Sara, Annelie
发明人： CHENG, Leifeng , HELGESSON, Sara, Annelie
IPC分类号： C07D471/04 , A61K31/437 , A61P3/04
CPC分类号： C07D471/04
摘要： Certain (4, 5, 6, 7) -tetrahydropyrrolo[3,2-c]pyridin-4-one and 4, 5 -dihydropyrrolo[3,2- c ]pyridin-4-one compounds of formula (I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, methods for their therapeutic use and pharmaceutical compositions containing them are described.
摘要翻译：将式（I）的某些（4,5,6,7）四氢吡咯并[3,2-c]吡啶-4-酮和4,5-二氢吡咯并[3,2-c]吡啶-4-酮化合物，为了制备这些化合物，描述了它们在治疗肥胖症，精神病学和神经病学障碍中的用途，其治疗用途的方法和含有它们的药物组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式